QALY variables related to HS, and events entered in the microsimulation model.

<p>HS: Health state; QALY: Quality-adjusted life years; CHD: Coronary heart disease; CKD: Chronic kidney disease; OI Opportunistic infection</p

Parameters used within the sensitivity analysis performed.

<p>CHD: Coronary heart disease; CKD: Chronic kidney disease; OI: Opportunistic infection; TC: Total cholesterol; HDL: High-density lipoprotein; HS: Health state; QALY: Quality-adjusted life years.</p>*<p>Ranges are: minimum and maximum or percentage variation of base-case values for uniform distributions; mean and standard deviation for normal distributions; alpha and beta are shape parameters for beta distributions.</p>‡<p>Risk values of diarrhoea, hyperbilirubinemia and opportunistic infections distributed according to a beta probability distribution.</p

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 1 regimens.

<p>Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 1 regimens.</p

Base-case estimates used within the model

<p>SD: standard deviation; DM: diabetes mellitus; CHD: Coronary heart disease; TC: Total cholesterol; HDL: High-density lipoprotein; VL: Viral load; HS: Health state; OI: Opportunistic infection; CKD: Chronic kidney disease</p>*<p>Estimates gathered from the literature and expressed as incidence rates (i.e., event/person-years) were converted into semestral probabilities using standard formulas</p>†<p>Transition probabilities of transitioning to a state with greater viral load (≥ 50 copies/mL) are 19% lesser than LPV/r</p>‡<p>Effect on TC:HDL ratio is considered null in second-line treatment</p

Lifetime results of the model divided per treatment.

<p>QALY: Quality-adjusted life years; CHD: Coronary heart disease; CKD: Chronic kidney disease; OI: Opportunistic infection; AE: Adverse event; VL: Viral load.</p

Structure of the microsimulation model at the individual level.

<p>Circle: event that does not determine a change of line of treatment. Rhombus: event that determine a change of line of treatment. HS: Health State. CHD: Coronary heart disease. CKD: Chronic kidney disease. OI: Opportunistic infection. VL: Viral load. § event that may lead to death. * Detectable viral load for two consecutive semesters. Patients enter the model being in first-line treatment (LPV/r or ATV+r). After each cycle, patients may change health state, die or experience events that may lead to a change in the line of treatment (patients in second-line had different treatment options that excluded those on first-line). Diarrhoea and hyperbilirubinemia may be experienced only by patients in first-line treatment, since these adverse events are associated with LPV/r and ATV+r therapies.</p

Costs of treatments and adverse events in euro for each Health State.

<p>Costs of treatments and adverse events in euro for each Health State.</p

Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 2 regimens.

<p>Incremental cost effectiveness ratio plan, presenting the results of the probabilistic sensitivity analysis of LPV/r vs. ATV+r 2 regimens.</p